^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYD1875

    i
    Other names: SYD1875, SYD 1875, anti 5T4 antibody drug conjugate
    Associations

    News

    Trials
    Company:
    Byondis
    Drug class:
    DNA replication inhibitor, 5T4-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    over2years
    [VIRTUAL] Preclinical Profile of SYD1875, a Novel Site- Specifically Conjugated Anti- 5T4 Antibody Drug Conjugate (ADC-USA 2021)
    Its preclinical profile supports the expectation that SYD1875 will be of benefit for a broad group of cancer patients. A first-in-human dose-finding trial is initiated to evaluate safety and explore efficacy (NCT04202705).
    Preclinical
    |
    TPBG (Trophoblast Glycoprotein)
    |
    SYD1875